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Recurrent pregnancy loss (RPL), either early or late in the gestational period, is a serious problem and has both 
psychological and social impacts on the women 
who suffer from it. In some cases, it may lead to 
divorce or other social problems.
Miscarriage is common, with most studies 
showing that the incidence of this complication 
occurring before 20 weeks’ gestation varies 
between 8–20%, with 80% of these occurring in 
the first 12 weeks of pregnancy.1 The real rate of 
miscarriage may be much higher than reported, 
since many women miscarry before realising that 
they are pregnant. In one study, human chorionic 
gonadotrophin was checked daily from the expected 
time of ovulation until the next menstrual period in 
order to detect a pregnancy as early as possible; this 
yielded a miscarriage rate of 31%.2
Habitual or recurrent miscarriage (RM) is 
defined as the loss of three or more consecutive 
and clinically-recognised pregnancies before 20 
weeks’ gestation; this affects 1–2% of women.3 This 
incidence increases to 5% when it is defined as a loss 
of two or more clinically-recognised pregnancies 
before 20 weeks’ gestation.4 RPL may be classified 
as early (losses at or before 20 weeks’ gestation) or 
late (losses after 20 weeks’ gestation). Patients may 
be classified as suffering from primary RPL when 
they have never had a live birth or from secondary 
RPL when they have had recurrent losses following 
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abstract: The association between thrombophilia and recurrent pregnancy loss (RPL) has become an 
undisputed fact. Thorombophilia creates a hypercoaguable state which leads to arterial and/or venous thrombosis 
at the site of implantation or in the placental blood vessels. Anticoagulants are an effective treatment against RPL 
in women with acquired thrombophilia due to antiphospholipid syndrome. The results of the use of anticoagulants 
for treating RPL in women with inherited thrombophilia (IT) are encouraging, but recently four major multicentre 
studies have shown that fetal outcomes (determined by live birth rates) may not be as favourable as previously 
suggested. Although the reported side-effects for anticoagulants are rare and usually reversible, the current 
recommendation is not to use anticoagulants in women with RPL and IT, or for those with unexplained losses. 
This review examines the strength of the association between thrombophilia and RPL and whether the use of 
anticoagulants can improve fetal outcomes.
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�إىل خثار يف  �لدم و بالتايل  �لتخرث يف  �إىل زيادة  �لتخرث  �أهبة  توؤدي  �لتخرث وفقد�ن �حلمل �ملتكرر هي حقيقة و�قعة.  �أهبة  �لعالقة بي  �إن  امللخ�ص: 
�ل�رش�يي �أو �الأوردة يف موقع �لعلوق �أو يف �الأوعية �لدموية للم�صيمة. تعمل �الأدوية �مل�صادة للتخرث بفعالية يف عالج فقد�ن �حلمل �ملتكرر عند �ل�صيد�ت 
�للو�تي يعاني من �أهبة �لتخرث �ملكت�صبة �لناجتة عن ظاهرة �الأج�صام �مل�صادة �ل�صحمية �لفو�صفورية .�إن نتائج �لدر��صات �لتي مت فيها ��صتعمال �الأدوية 
�مل�صادة للتخرث ملعاجلة فقد�ن �حلمل �ملتكرر كانت م�صجعة للغاية حتى �صدور �أربعة در��صات كربى متعددة �ملر�كز بينت �أن ن�صبة �ملو�ليد �الأحياء رمبا 
ال تكون م�صجعة كما كان يعتقد �صابقا. على �لرغم من �أن �مل�صاعفات و�الأعر��س �جلانبية لتلك �الأدوية نادرة �حلدوث ولي�صت خطرية فان تلك �لدر��صات 
ال تو�صي با�صتعمال �الأدوية �مل�صادة للتخرث لعالج �الأمهات �للو�تي يعاني من فقد�ن �حلمل �ملتكرر �أهبة �لتخرث �لور�ثية لعالج فقد�ن �حلمل �ملتكرر 
�لذي ال يعرف له �صبب.
مفتاح الكلمات: �أهبة �لتخرث؛ �حلمل �ملتكرر؛ �لهيبارين ذو �لوزن �جلزيئي �ملنخف�س؛ �الأ�صربين �ملعتاد.
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a successful pregnancy. RPL has now been deemed 
a major cause of female infertility.5
Thrombophilia is a common cause of RPL and 
may be seen in 40–50% of cases.6,7 Pregnancy is 
a hypercoaguable state and if the pregnancy is 
affected by thrombophilia, the hypercoaguable state 
becomes worse and may impair blood flow through 
the maternal veins, leading to deep vein thrombosis, 
and clots in the placental blood vessels, leading 
to fetal growth restriction and/or fetal demise.8,9 
Due to this fact, anticoagulants have become very 
popular for treating RPL.
The aim of this review is to find the strength of 
the association between thrombophilia and RPL 
and whether the use of anticoagulants can improve 
fetal outcomes.
Thrombophil ia
Thrombophilia is a term which describes the 
increased tendency of excessive blood clotting. It 
is a normal phenomenon during pregnancy, where 
there is an increase in most clotting factors, such 
as factor VIII, Von Willebrand factor, platelets, 
fibrinogen and factor VII. During pregnancy, there 
is also an increase in prothrombin fragment 1 + 2 
and D-dimer.10,11
When investigating patients with RPL, it is 
very important to exclude other possible causes of 
the losses, such as uterine malformation; diabetes 
mellitus; connective tissue diseases such as 
systemic lupus erythematosus (SLE); chromosomal 
abnormalities, and thyroid dysfunction.12–15
Currently, many clinicians treat RPL—either 
associated with all types of thrombophilia or 
unexplained—with low-molecular-weight heparin 
(LMWH) combined with low-dose aspirin (LDA). 
This treatment became popular in the late 1990s, 
after Sanson et al. reported that thrombophilia is 
associated with the high risk of fetal loss in early and 
late pregnancy.16 Thrombophilia is either inherited, 
acquired or a combination of both.
inherited or genetic 
thrombophilia
In inherited or genetic thrombophilia, there is 
usually a family history of excessive clotting. 
More commonly, the diagnosis is based on the 
demonstration of a gene mutation such as a 
Factor V Leiden (FVL) mutation (C677T), a 
hyperhomocysteinaemia mutation (A506G), a 
prothrombin mutation (G20210A) or prothrombin 
II (PTII) mutation, or a protein S and/or C 
deficiency.
Clinical studies suggest that hypercoagulation is 
the main underlying pathophysiological mechanism 
which leads to uteroplacental insufficiency and, 
subsequently, pregnancy loss. It is believed that 
inherited thrombophilia (IT) impairs the placental 
function by causing arterial and/or venous 
thrombosis at the maternal-fetal interface. It is 
also believed that activated protein S and protein 
C inhibit the action of certain clotting factors, such 
as factors V and VIII. This shows that proteins S 
and C act as anticoagulants. If the actions of these 
proteins are reduced, the inhibition of the clotting 
mechanism is removed and, subsequently, placental 
arterial and venous thrombosis may occur; this 
mechanism might be the basis of RPL associated 
with thrombophilia.
When there is a mutation of the FVL gene 
(arginine amino acid is substituted by glutamine 
amino acid at position number 506 of factor V), 
this may result in the formation of a protein which 
is resistant to the action of activated protein C, 
called anti-protein C (aPC). The aPC removes 
the inhibitory effect of protein C on the clotting 
mechanism and enhances the conversion of 
prothrombin to thrombin, subsequently enhancing 
the formation of clots.17–19 This absent or reduced 
activity of antithrombin leads to increased levels of 
thrombin and clot formation.
A mutation of the prothrombin gene (G20210A) 
will facilitate the formation of thrombin and clot 
formation in heterozygous individuals, who have 
a two-fold higher risk of clotting in comparison to 
non-carriers. Women with hyperhomocysteinaemia 
show a folic acid deficiency, also resulting in a 
two-fold increase in clotting within homozygous 
women.20–23
The exact mechanism by which IT causes 
implantation failure and subsequent RPL is unclear. 
It has been suggested that thrombophilia may lead 
to a syncytiotrophoblast invasion of the maternal 
blood vessels, which in turn leads to the formation 
of microthrombosis at the site of implantation, 
resulting in implantation failure and RPL.24
In a study of the effect of ethnicity on RM and IT, 
Baumann et al. found that in a uniform ethnic group 
the prevalence of various congenital thrombophilic 
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combination of acquired and IT, or a combination 
of more than one inherited thrombophilic gene 
defect) has been identified by several researchers 
as a cause of both early and late RPL; however, 




Heparin exerts an effect on women with 
thrombophilia through various mechanisms; 
it potentiates the antithrombin effects of the 
condition, thus preventing clot formation.38
Heparin also binds to the aPL, rendering them 
inactive; this is important as these antibodies adhere 
to the cell surface and impede the differentiation 
and invasiveness of the cytotrophoblasts. It has 
been reported that low-molecular-weight heparin 
(LMWH) reduces the binding of the aPL to the 
trophoblast cells, subsequently restoring the 
cytotrophoblasts’ invasiveness and differentiation.39 
Unfractionated and LMWH reduce E-cadherin 
protein expression in rat pregnancies. This may 
enhance the trophoblast invasion in patients with 
pregnancy loss.40
The treatment of women with APS and RPL 
with heparin is beneficial because complement 
activation is essential for the aPL to induce fetal 
damage; heparin, whether fractionated or LMWH, 
inhibits the complement activation in vivo and 
in vitro in pregnant mice, thus preventing fetal 
damage.41
In the absence of aPL, LMWH induces a 
potentially detrimental proinflammatory and 
anti-angiogenic profile in the trophoblast. In the 
presence of aPL, single-agent LMWH may be 
the optimal therapy to counter the trophoblast 
inflammation, however it also induces an anti-
angiogenic response.42
Treatment of Women 
with Antiphospholipid 
Syndrome and Recurrent 
Pregnancy Loss
The evidence in the literature favours treating aPL-
positive women with APS who are suffering from 
RPL. The Cochrane review by Empson et al. was 
conducted to assess the efficacy of all treatment 
markers did not differ. Thus, when investigating a 
multi-ethnic cohort of women, the prevalence of 
hereditary thrombophilia may differ due to the fact 
that the basic prevalence in different ethnic groups 
varies.25 The prevalence of thrombophilia in the 
general population varies from 1.1% in Lebanon to 
2.5% in India.26,27
In acquired thrombophilia, antiphospholipid 
syndrome (APS) can be due to either lupus 
anticoagulant antibodies or anticardiolipin 
antibodies, as seen in women with SLE. In 
APS, the body’s immune system recognises 
the phospholipids, which are a part of the 
cell membrane, as a foreign substance and thus 
produces antibodies against them. However, other 
studies have shown that antiphospholipid antibodies 
(aPL) often act against a protein cofactor called β2-
glycoprotein 1. This protein cofactor helps the aPL to 
adhere to the phospholipids in the cell membrane.28 
The aPL consist of 20 antibodies, but only the 
lupus anticoagulant and anticardiolipin antibodies 
(immunoglobulin G and immunoglobulin M, but 
not immunoglobulin A [IgA]) have been shown to 
be of clinical significance.29,30 In one study, 55% of 
women with RPL tested positive for aPL.31
In women with SLE, adverse live-birth outcomes 
were significantly associated with posititive 
anticardiolipin IgA and anti-beta 2 glycoproteins.32 
The mechanism by which APS causes implantation 
failure and subsequent RPL is unclear. It has 
been suggested that, as in thrombophilia, APS 
may lead to a syncytiotrophoblast invasion of the 
maternal blood vessels, leading to the formation 
of microthrombosis at the site of implantation, 
resulting in implantation failure and RPL.24
Histopathological examinations of the placentas 
in women with APS showed thrombosis, acute 
atherosis, a decreased number of syncytiovascular 
membranes, an increased number of syncytial 
knots and obliterative arteriopathy. These placental 
changes, although common, are not specific to 
APS.33
It has been suggested that in women with APS 
and RPL, the presence of aPL during pregnancy is 
a major risk factor for adverse fetal outcomes.34 In 
a recent study, the incidence of aPL was 27.8% in 
couples with RPL.35
combined thrombophilia
Combined thrombophilia (which is either a 
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options in order to improve pregnancy outcomes 
in aPL-positive women suffering from RPL.43 The 
studies reviewed were either randomised or quasi-
randomised studies of pregnant women with a 
history of RPL and aPL. The selection criteria 
(women with RPL and APS with positive aPL) 
(N = 849) were fulfilled in 13 studies. They found that 
combining unfractionated heparin with LDA (two 
trials; n = 140) resulted in a significant reduction in 
pregnancy loss when compared to a trial in which 
patients used LDA alone (relative risk [RR] = 0.46; 
95% confidence interval [CI]: 0.29–0.71). One trial 
(N = 98) compared pregnancy loss outcomes when 
LMWH was combined with LDA in one group and 
LDA was given alone in another group. This did not 
show a significant reduction in pregnancy loss rate 
(RR = 0.78: 95% CI: 0.39–.57). One trial (N = 50) 
failed to show any advantage in giving high-dose or 
low-dose unfractionated heparin. The use of LDA 
alone was reported in three trials (N = 135) and 
these showed no significant reduction in pregnancy 
loss (RR = 1.05; 95% CI: 0.66–1.68). Treatment with 
prednisone and LDA was reported in three trials 
(N = 286). The results showed a significant increase 
in prematurity with LDA alone in comparison 
to a combination of heparin with LDA, and both 
of these treatment options were compared to a 
placebo. In fact, there was an increase in gestational 
diabetes. Intravenous immunoglobulin and/
or unfractionated heparin and LDA were used 
in two trials (N = 58). This was associated with a 
higher frequency of pregnancy loss and premature 
deliveries when compared to unfractionated 
heparin or LMWH combined with LDA (RR = 2.51; 
95% CI: 1.27–4.95). When compared to LDA alone 
and prednisone alone, intravenous immunoglobulin 
(one trial; N = 82) showed no significant difference 
in outcome. The authors concluded that the 
combination of unfractionated heparin and LDA 
may reduce pregnancy loss by 54% in women with 
APS and who are aPL-positive.
Mak et al. conducted a meta-analysis of 
studies involving women with RPL who were aPL-
positive.44 The study (N = 334) was conducted in 
order to ascertain whether the combination of 
heparin and LDA worked better than LDA alone 
to achieve live births. The authors found that the 
overall frequency of live births was 74.27% in 
women who used the combination compared to 
55.83% in the group using LDA alone. Women who 
received a combination of heparin and LDA had 
a significantly higher live birth rate (RR = 1.301; 
95% CI: 1.040, 1.629) than women who used LDA 
alone. The authors concluded that the combination 
of heparin and LDA resulted in more live births in 
aPL-positive women than using LDA alone.
In Cohn et al.’s study (N = 693), only 176 women 
(25%) were aPL-positive, while the rest had 
unexplained RPL.45 Of the aPL-positive women, 69% 
(n = 122) had a subsequent live birth compared with 
63% (n = 324) of the women with unexplained RPL 
(odds ratio [OR] = 1.3; 95% CI: 0.9–1.9). When the 
authors analysed the results, they found that 79% 
of aPL-positive women receiving a combination of 
heparin and LDA had a live birth compared with 
62% of those receiving LDA alone (adjusted OR = 
2.7; 95% CI: 1.3–5.8). In the unexplained RPL group, 
there was no difference in outcome for women 
receiving a combination of heparin and LDA or 
LDA only. The authors concluded that a combined 
Table 1: Live birth rates in women with antiphospholipid syndrome  and recurrent pregnancy loss treated with low-
molecular-weight heparin plus low-dose aspirin compared with those treated with low-dose aspirin alone































LMWH = low-molecular-weight heparin; LDA = low-dose aspirin.
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Is Inherited Thrombophil ia 
Associated with Recurrent 
Pregnancy Loss?
The following studies, all of them prospective case-
control studies, did not find an association between 
IT and adverse pregnancy outcomes.
In Said et al.’s prospective cohort study, 
2,034 nulliparous women were recruited 
before 22 weeks’ gestation.48 Genotyping for 
FVL mutations, mutations of the prothrombin 
gene, methylenetetrahydrofolate reductase 
enzymes (MTHFR) C677T, MTHFR A1298C 
and thrombomodulin polymorphisms were 
performed. The thrombophilia investigation 
results were disclosed neither to the women nor 
to their physicians. The thrombophilia tests results 
and pregnancy outcomes were available in 1,707 
women. Pregnancy complications such as placental 
abruption, severe pre-eclampsia, intrauterine 
growth restriction, stillbirths and early neonatal 
deaths occurred in 136 women (8%). The authors 
concluded that the majority of asymptomatic 
women with IT will have a successful pregnancy 
outcome.
Silver et al.’s study tried to ascertain whether 
women carrying mutations of the prothrombin 
gene G20210A were at higher risk of RPL, placental 
abruption, severe pre-eclampsia or intrauterine 
growth restriction.49 They recruited 5,188 women, 
and 4,167 blood samples were taken in the first 
trimester and analysed for the gene mutation 
G20210A. In this study, only 3.8% of the women 
tested had a mutation of prothrombin G20210A 
and their pregnancy loss rates were similar to those 
of women without the mutation. The authors thus 
concluded that the prothrombin gene mutation 
G20210A was not associated with pregnancy loss 
or the other obstetric complications studied.
Dizon-Townson et al. studied pregnancy rates 
among women who were heterozygous carriers of 
the FVL mutation.50 Only women with singleton 
pregnancies before 14 weeks’ gestation were 
enrolled. In this study, the researchers failed to show 
any increase in pregnancy loss or other obstetric 
complications. such as pre-eclampsia, placental 
abruption or intrauterine growth restriction, when 
compared with non-carriers. They concluded that 
women who are heterozygous carriers of the FVL 
gene mutation do not require either screening or 
treatment of LDA and heparin is superior to LDA 
alone in aPL-positive women, but not for women 
with unexplained RPL.
In their study, Al Abri et al. analysed the 
outcomes of pregnancies in a cohort of 21 Arab 
women and four women from other parts of Asia, 
who had had one or more episodes of fetal loss 
associated with raised levels of anticardiolipin 
antibodies.46 They found that the rate of pregnancy 
loss was significantly higher in the first trimester 
than in the second or third. In the group that had 
received both LDA and prednisolone, 75% of 
pregnancies were successful compared to 54% 
in the group receiving aspirin alone, while 17% 
were successful in those who received no therapy. 
They concluded that LDA, either alone or with 
prednisolone, appears to improve significantly 
the chances for successful pregnancies in patients 
with anticardiolipin antibodies. The results of these 
studies are summarised in Table 1.
Which Heparin should 





One question to consider is which heparin should 
be used in women with APS and who are positive 
for aPL. In Fouda et al.’s study, 60 women with a 
history of three or more consecutive pregnancy 
losses and positive for aPL were divided equally into 
two groups.47 One group received  unfractionated 
heparin (5,000 units, twice daily) plus LDA. The 
second group received LMWH (enoxaparin 40 
mg, once daily) plus LDA immediately after their 
pregnancy was confirmed. The authors found that 
25 of the women who received LMWH (80%) and 20 
of the women who received unfractionated heparin 
(66.67%) had successful pregnancies and deliveries 
(P = 0.243). The authors concluded that LMWH 
plus LDA was a better alternative to unfractionated 
heparin plus LDA. Another advantage of LMWH is 




treatment during pregnancy if there is no history of 
thromboembolisms.
Roqué et al. studied the association between 
inherited and acquired maternal thrombophilias 
and adverse pregnancy events.51 A cohort of 491 
patients with a history of adverse pregnancy 
outcomes was evaluated for activated protein 
C resistance, FVL and prothrombin G20210A 
mutations, hyperhomocysteinaemia, antithrombin 
deficiencies, proteins C and S, and both 
anticardiolipin antibodies and lupus anticoagulants. 
They found that the presence of maternal 
thrombophilia was not associated with an increased 
risk of fetal loss before 14 weeks’ gestation.
Prospective case-control studies that showed 
an association between IT and adverse pregnancy 
outcomes were also found, and are summarised 
below.
In Preston et al.’s study, 1,384 women were 
enrolled in the European Prospective Cohort on 
Thrombophilia.52 They found an increased risk 
of fetal loss in women with IT (168/571 versus 
93/395; OR = 1.35; 95% CI: 1.01–1.82). The OR 
was greater for stillbirths than for miscarriages (3.6 
[1.4–9.4] versus 1.27 [0.94–1.71]). The highest OR 
for stillbirth was in women with combined defects 
at 14.3 (2.4–86.0), which can be compared with 5.2 
(1.5–18.1) in those with antithrombin deficiencies; 
2.3 (0.6–8.3) in those with protein C deficiencies; 
3.3 (1.0–11.3) in those with protein S deficiencies, 
and 2.0 (0.5–7.7) in those with FVL mutations. 
The OR for miscarriage in these subgroups was 
0.8 (0.2–3.6) in women with combined defects; 1.7 
(1.0–2.8) in those with antithrombin deficiencies; 
1.4 (0.9–2.2) in those with protein C deficiencies; 
1.2 (0.7–1.9) in those with protein-S deficiencies, 
and 0.9 (0.5–1.5) in women with FVL mutations. 
The authors concluded that women with familial 
thrombophilia, especially those with combined 
defects or antithrombin deficiencies, have an 
increased risk of fetal loss.
Kocher et al. studied 5,000 pregnant women 
and found a significant association between FVL 
mutations and stillbirths (OR = 19.9; 95% CI: 
2.07–56.94), but not early fetal loss (OR = 1.76; 95% 
CI: 0.85–3.65).53
Sottilotta et al.’s study included 102 consecutive 
women with pregnancy loss who were tested for 
thrombophilia. Of these, 55 women with RPL 
(47 of whom had had a stillbirth) were tested for 
thrombophilia.54 They found that the prevalence of 
prothrombin II, FVL and prothrombin G20210A 
mutations was higher in women with unexplained 
stillbirths. This finding was statistically significant. 
The prevalence of IT thrombophilia was higher 
in women with RPL, but the difference was not 
statistically insignificant.
Treating Recurrent 
Pregnancy Loss in Cases 
of Inherited Thrombophil ia
There are a few studies that show that treating 
women who suffer from IT and RPL with 
anticoagulants is beneficial; however, these studies 
have many limitations.
The LIVE-ENOX study compared two doses of 
LMWH (enoxaparin, 40 versus 80 mg) for women 
with and without thrombophilia.55 Treatment 
with LMWH commenced between 5–10 weeks’ 
gestation. The prevalence of thrombophilia was 
similar in both treatment groups and the live birth 
rate was 84.3% in women who received 40 mg of 
enoxaparin and 78.3% in women who received 
80 mg of enoxaparin. Live birth rates were 70.0%, 
84.4%, 76.9% and 81.3% for women with FVL 
mutations, hyperhomocysteinaemia, APS and other 
types of thrombophilia, respectively. The differences 
in these live birth rates were not significant 
(P = 0.484). The major limitation of this study was 
that the researchers did not compare LMWH with 
either LDA or a placebo.
In Deligiannidis et al.’s study, all of the subjects 
had RM and IT. The women in the experimental 
group (n = 29) received a combination of LMWH 
and LDA, while the control group (n = 23) received 
no treatment.56 There was a significantly lower 
miscarriage rate among the women who received 
LMWH plus LDA when compared with those who 
received no treatment. However, the study was not 
randomised.
In Carp et al.’s cohort study, 58 women who had 
RM and IT were investigated.57 Within this cohort, 
37 received 40 mg of enoxaparin and 48 received 
no treatment. They found that 26 out of 37 (70.2%) 
of the women who received LMWH had live births 
compared with 21 out of 48 (43.8%) untreated 
women. (P <0.02; OR = 3.03; 95% CI: 1.12–8.36). 
The limitation of this study was that it was neither 
controlled nor randomised.
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scan. Live birth rates were 85% in the combined 
therapy group and 81% in the LMWH alone group 
compared to 48% in women who received the 
placebo (P <0.05).
The results of these studies are summarised in 
Table 2 and all show a favourable outcome in women 
with RPL, either with or without thrombophila.
Prescribing 
Anticoagulants to Women 
with Recurrent Pregnancy 
Loss: Is the current 
practice justif ied?
Because of the results of the previously summarised 
investigations, the majority of clinicians worldwide 
have started prescribing heparin and/or aspirin for 
pregnant women with RPL, either with or without 
thrombophilia. However, because of the limitations 
of these studies, many researchers have conducted 
controlled, randomised, double-blind, multicentre 
studies to find out whether the current practice of 
prescribing anticoagulants to women with RPL with 
or without thrombophilia is justified. Those studies 
and their results are summarised below [Table 3].
The Scottish Pregnancy Intervention (SPIN) 
study was a multicentre, randomised, controlled 
trial of LMWH and LDA in women with RM.60 This 
study included 294 women at less than seven weeks’ 
gestation. All of the women had had two or more 
consecutive pregnancy losses before 24 weeks’ 
gestation. Other causes of RPL were excluded, such 
as RPL due to endocrinological, chromosomal, 




The use of LMWH in the treatment of patients with 
RPL without identified thrombophilia is based on 
two retrospective studies that reported a higher rate 
of successful pregnancy outcomes. Both studies had 
methodological limitations.
In Badawy et al.’s prospective randomised 
study, 340 women with first-trimester RM with no 
identifiable cause were investigated.58 The women 
were randomised into two groups, with one group 
receiving LMWH and folic acid while the other 
group received only folic acid. In the LMWH group, 
treatment commenced once the fetal heartbeat was 
visible by ultrasound scan and continued until 34 
weeks’ gestation. Folic acid was discontinued at 13 
weeks’ gestation in both groups. The researchers 
found that the early miscarriage rate was 4.1% 
in the combined LMWH and folic acid group as 
compared with 8.8% in the folic acid alone group, 
while late pregnancy loss was 1.1% in the combined 
group compared with 2.3% in the folic acid alone 
group. This study showed modest improvements in 
the rates of pregnancy loss in women with RPL in 
the first trimester without thrombophilia (live birth 
risk ratio = 1.07; 95% CI: 1.00–1.14).
In Fawzy et al.’s prospective randomised, single-
blinded, placebo-controlled study, 160 women 
diagnosed with idiopathic RM (more than three 
miscarriages) were recruited.59 They received either 
LMWH (enoxaparin) alone; prednisone, LDA and 
progesterone, or a placebo in treatment, once the 
pregnancy had been confirmed by an ultrasound 
Table 2: Pregnacy outcomes in women with idiopathic recurrent pregnancy loss treated with low-molecular-weight 
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Women were randomised into two groups. Group 
one received LMWH and LDA (40 mg of enoxaparin 
and 75 mg of aspirin daily) until 36 weeks’ gestation 
with intensive surveillance, while group 2 had 
only intensive surveillance during the pregnancy. 
After randomisation, blood was sent from all of 
the women for thrombophilia testing. The results 
were not disclosed, either to the patient or to the 
clinician, until six weeks after the delivery. In this 
study, 10 women had IT, eight were heterozygous 
carriers of FVL mutations and five were identified 
in the pharmacological intervention group. Two 
cases had the prothrombin G20210A mutation, 
with one identified in each arm of the trial. The 
authors found that the pregnancy loss rate was 22% 
in women receiving both LMWH and LDA, while 
the pregnancy loss rate was 20% in the group who 
were only intensively monitored. They concluded 
that their results do not support the use of LMWH 
and/or LDA in women with RPL not due to APS.
In Kaandorp et al.’s randomised Anticoagulants 
for Living Fetuses (ALIFE) trial, the participants 
(n = 364) all had a history of unexplained RPL.61 
They were randomised equally into three groups. 
Group 1 received a daily dose of 80 mg of aspirin 
plus LMWH (2,850 IU) daily, group 2 received 
a daily dose of 80 mg of aspirin only and group 
3 received a placebo. In this study, 299 women 
became pregnant. The live birth rates were similar 
in the three groups, with 69.1% (67/97) in group 
1, 6% (61/99) in group 2 and 67.% (69/103) in group 
3. This study showed that neither a combination of 
LMWH and LDA nor LDA alone improved the live 
birth rate when compared with the use of a placebo 
in women with RPL.
In Visser et al.’s Low Molecular Weight 
Heparin and/or Aspirin in Prevention of Habitual 
Abortion (HABENOX) study, a randomised, 
double-blind, multicentre study, 207 women were 
recruited.7 All had had three or more consecutive 
miscarriages in the first trimester (less than 13 
weeks’ gestation), or two or more second trimester 
consecutive miscarriages. All women were tested 
for thrombophilia and were randomised before 
seven weeks’ gestation to receive either LMWH (40 
mg of enoxaparin) plus a placebo (n = 68), LMWH 
(40 mg of enoxaparin) plus 100 mg of aspirin (n = 
63) or 100 mg of aspirin alone (n = 76). The live 
birth rate was 71% in women who received LMWH 
plus a placebo, 65% for those who received LMWH 
plus LDA and 61.5% in those who received LDA 
alone. The differences in the live birth rates were 
not statistically significant among the three groups, 
regardless of their thrombophilic statuses.
The Heparin and Aspirin (HepASA) trial studied 
88 pregnant women with RPL who were either aPL-
positive, or who had IT or antinuclear antibodies.62 
Women were randomised into two groups, with 
group one (n = 45) receiving LMWH plus LDA 
while group two (n = 43) received LDA alone. In 
each group, 47.7% of women were aPL-positive. 
The live birth rate was 77.8% (35/45) in group 1 and 
79.1% (34/43) in group 2. The authors concluded 
that LMWH plus LDA showed no benefit over LDA 
alone in women with RPL.
Table 3: A review of controlled, randomised, double-blind, multicentre studies to determine whether prescribing 
anticoagulants to women with recurrent pregnancy loss, with or without thrombophilia, is justified
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Conclusion
In women with RPL associated with IT, LMWH 
therapy has been shown to improve live birth rates 
when compared to LDA or a placebo. However, 
LMWH for women with RPL which is not associated 
with APS it is not recommended. In women with 
RPL and APS, LMWH can be used as early as six 
weeks’ gestation until 34–36 weeks’ gestation.
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